anti-PLOD2 antibody product blog
Tags: Antibody; Monoclonal Antibody; anti-PLOD2 antibody; PLOD2;
The PLOD2 plod2 (Catalog #MBS2537475) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The PLOD2 Monoclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s PLOD2 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunohistochemistry (IHC), ELISA (EIA).WB: 1:1000-1:10000
IHC: 1:100-1:400. Researchers should empirically determine the suitability of the PLOD2 plod2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The PLOD2 plod2 product has the following accession number(s) (GI #62739166) (NCBI Accession #NP_000926.2) (Uniprot Accession #O00469). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the PLOD2 Monoclonal Antibody with the following immunoassay(s):
Western Blot (WB) (Western Blot analysis of DU 145 cells using PLOD2 Monoclonal Antibody at dilution of 1:2000)
PLOD2, also named as LH2, forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. It is a potential novel prognostic factor for HCC patients following surgery. Among the PLOD genes, PLOD2 contributes to cancer prognosis and angiogenesis. Several authors have reported that PLOD2 expression might provide prognostic information about malignant tumours such as glioblastoma. PLOD2 expression is an useful biomarker for the effects of antiangiogenic treatment for malignancy. It has 2 isoforms produced by alternative splicing and seven glycosylation sites.
Immunogen: Fusion protein of PLOD2. Buffer: PBS with 0.02% sodium azide, 50% glycerol, PH7.3
Conjugation: Unconjugated. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PLOD2 are readily searchable from our website. Different antibodies against the same target such as PLOD2 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Adipose Tissue, Bone, Bone Marrow, Brain, Connective Tissue, Embryonic Tissue, Liver, Muscle, Skin, Vascular tissues are correlated with this protein. The following patways have been known to be associated with this gene. Adenocarcinoma, Bruck syndrome 2, Cardiovascular Diseases, Congenital Abnormalities, Fibrosis, Liver Diseases, Necrosis, Neoplasm Metastasis, Neoplasms, Neoplasms, Experimental are some of the diseases may be linked to PLOD2 Monoclonal Antibody. PLOD2 also interacts with the following gene(s): PLOD3.